Xcell Therapeutics Inc. Q3 revenue KRW 1.1 billion, operating loss KRW 3.0 billion
AI summary · Not investment advice
Excel Therapeutics sold KRW 1.1 billion in Q3 and lost KRW 3.0 billion from its main business, versus a KRW 2.4 billion loss a year earlier.
Operating profit · 3 months
KRW -3.0 billion
Key facts
- Revenue (3 months)
- KRW 1.1 billion
- Net income (3 months)
- KRW -3.1 billion
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 334.6 million
- Revenue (year to date)
- KRW 4.0 billion
- Operating profit (prior-year 3 months)
- KRW -2.4 billionOperating loss
- Operating profit (year to date)
- KRW -8.7 billionOperating loss
- Net income (prior-year 3 months)
- KRW -2.3 billionQuarterly net loss
- Net income (year to date)
- KRW -8.7 billionQuarterly net loss
Commentary
AI commentary · Not investment advice
What happened
Excel Therapeutics reported its third-quarter results on a consolidated basis. Sales for the latest 3 months were KRW 1.06 billion. That is up 217.9% from the same 3 months a year earlier (KRW 334.6 million) and down 45.1% from the previous quarter.
In the company's terms
Operating profit (profit from the core business) was a loss of KRW 2.98 billion for the 3 months. A year earlier, the loss was KRW 2.38 billion. Net income, the final profit after everything, was a loss of KRW 3.06 billion. A year earlier, the net loss was KRW 2.31 billion.
What changes for shareholders
For the cumulative period from Jan 1 to Sep 30, sales were KRW 4.02 billion. Operating profit was a loss of KRW 8.65 billion. Net income was a loss of KRW 8.75 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
X